By a News Reporter-Staff News Editor at Life Science Weekly -- Data detailed on Peptide Proteins have been presented. According to news reporting originating in Malov, Denmark, by NewsRx journalists, research stated, "Chitosan nanoparticles (NC) have excellent capacity for protein entrapment, favorable epithelial permeability, and are regarded as promising nanocarriers for oral protein delivery. Herein, we designed and evaluated a class of core shell corona nanolipoparticles (CSC) to further improve the absorption through enhanced intestinal mucus penetration."
The news reporters obtained a quote from the research from Novo Nordisk, "CSC contains chitosan nanoparticles as a core component and pluronic F127-lipid vesicles as a shell with hydrophilic chain and polyethylene oxide PEO as a corona. These particles were developed by hydration of a dry pluronic F127-lipid film with NC suspensions followed by extrusion. Insulin nested inside CSC was well protected from enzymatic degradation. Compared with NC, CSC exhibited significantly higher efficiency of mucosal penetration and, consequently, higher cellular internalization of insulin in mucus secreting E12 cells. The cellular level of insulin after CSC treatment was 36-fold higher compared to treatment with free insulin, and 10-fold higher compared to NC. CSC significantly facilitated the permeation of insulin across the ileum epithelia, as demonstrated in an ex vivo study and an in vivo absorption study. CSC pharmacological studies in diabetic rats showed that the hypoglycemic effects of orally administrated CSC were 2.5-fold higher compared to NC."
According to the news reporters, the research concluded: "CSC is a promising oral protein delivery system to enhance the stability, intestinal mucosal permeability, and oral absorption of insulin."
For more information on this research see: Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials, 2013;34(37):9678-9687. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news correspondents report that additional information may be obtained by contacting X.Y. Li, Novo Nordisk AS, Oral Formulat Dev, DK-2760 Malov, Denmark. Additional authors for this research include S.Y. Guo, C.L. Zhu, Q.L. Zhu, Y. Gan, J. Rantanen, U.L. Rahbek, L. Hovgaard and M.S. Yang (see also Peptide Proteins).
Keywords for this news article include: Malov, Europe, Denmark, Treatment, Proinsulin, Nanoparticle, Nanotechnology, Peptide Hormones, Peptide Proteins, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC